Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Çakmak, Mehmet Erdem; Kaya, Serdar; Bostan, Özge Can; Tuncay, Gülseren; Damadoğlu, Ebru; Karakaya, Gül; Kalyoncu, Fuat

doi:10.21911/aai.584

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No intensive care unit admissions were reported. Secondly, treatment with biological therapy, compared to inhaled corticosteroids -long acting beta agonist (ICS-LABA) alone, did not increase the risk of SARS-CoV-2 infection 30 .…”

Section: Discussionmentioning

confidence: 98%

COVID-19 in severe asthma treated with omalizumab: The Maltese perspective

Sciberras¹,

Gouder²,

Montefort³

2021

Pneumon

View full text Add to dashboard Cite

INTRODUCTION SARS-CoV-2 was identified as the causative agent of the COVID-19 pandemic, which has been the focus of extensive research for over a year. Asthmatics were listed as a high-risk group for susceptibility to SARS-CoV-2. Several hypotheses have been proposed regarding protective factors in asthmatics, amongst which were the role of biological agents. One such agent is omalizumab, an IgE inhibitor, which is currently the only biological agent available in Malta for the treatment of severe asthma. METHODS This study aims to evaluate the symptomatology and disease course of SARS-CoV-2 in our cohort of severe asthmatic patients on omalizumab that contracted COVID-19. Molecular diagnostic tests (SARS-CoV-2 PCR tests taken, if any, and the PCR result) since March 2020 of all adult patients receiving omalizumab for severe allergic asthma in January 2021, were reviewed from I-soft Clinical Manager®. Demographic data were collected for those patients who were found to be positive. RESULTS Our cohort included 58 patients, of whom 43 had PCR tests. Of these, 7 patients (12%) tested positive during the study period. Results show a male predominance in the cohort, with fever being the commonest symptom, and a mortality of only 1 patient out of 7. CONCLUSIONS From the small number of our severe asthmatic patients infected with SARS-CoV-2 whilst receiving omalizumab, the majority had only mild symptoms, with minimal effect on asthma-related symptoms and hospitalizations, apart from mortality in one patient.

show abstract

Section: Discussionmentioning

confidence: 98%

COVID-19 in severe asthma treated with omalizumab: The Maltese perspective

Sciberras¹,

Gouder²,

Montefort³

2021

Pneumon

View full text Add to dashboard Cite

show abstract

“…In allergic asthmatic patients, allergic sensitization and eosinophilic inflammation can disrupt the integrity of the airway epithelium, thereby paving the way for limiting the ability of virus clearance and fostering the location of viruses in the lower respiratory tract. Therefore, biologic agents, such as omalizumab (an anti-IgE antibody) and mepolizumab (a monoclonal antibody to IL-5), used in the treatment of severe allergic or eosinophilic asthma, may improve the prognosis of COVID-19 (24,25). This would decrease the risk of COVID-19-related anxiety because…”

Section: Discussionmentioning

confidence: 99%

The Impact of SARS-CoV-2 Transmission Fear and the COVID-19 Pandemic on the Mental Health of Patients with Primary Immunodeficiency Disorders and Severe Asthma, and Other High-Risk Groups

Çölkesen

Kılınçel

Sözen

et al. 2021

Asthma Allergy Immunol

View full text Add to dashboard Cite

Objective: The effect of the COVID-19 pandemic on mental health in the long term is unclear. We evaluated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)–related transmission fear and mental-health disorders in populations at high risk for COVID-19. Materials and Methods: Healthcare workers and patients with primary immunodeficiency disorders (PIDs), severe asthma, malignancy, cardiovascular disease, hypertension, and diabetes mellitus were included in the study. The hospital anxiety and depression scale (HADS) and Fear of Illness and Virus Evaluation (FIVE) scales were applied during face-to-face interviews. Results: There was a total of 560 participants, 80 per group; 306 (55%) were female. The FIVE and HADS-A scale scores of health care workers were significantly higher than the other groups (p = 0.001 and 0.006). The second-highest scores were in patients with PID. There was no significant difference between the groups in HADS-D scores (p = 0.07). There was a significant positive correlation between FIVE scale scores and anxiety (r = 0.828; p < 0.001) and depression (r = 0.660; p < 0.001). The FIVE scale had significant discriminatory power for anxiety (AUC = 0.870, 95% confidence interval [CI] = 0.836–0.904; p < 0.0001) and depression (area under the curve = 0.760, 95% CI = 0.717–0.803; p < 0.0001). Conclusion: During the COVID-19 pandemic, mental-health disorders may develop in patients with comorbidities, especially healthcare workers. They should be referred to mental-health centers. Keywords: Asthma, COVID-19, fear of virus transmission, mental health, primary immunodeficiency

show abstract

Dexamethasone/favipiravir/hydroxychloroquine

2022

Reactions Weekly

View full text Add to dashboard Cite

Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Cited by 5 publications

References 9 publications

COVID-19 in severe asthma treated with omalizumab: The Maltese perspective

COVID-19 in severe asthma treated with omalizumab: The Maltese perspective

The Impact of SARS-CoV-2 Transmission Fear and the COVID-19 Pandemic on the Mental Health of Patients with Primary Immunodeficiency Disorders and Severe Asthma, and Other High-Risk Groups

Dexamethasone/favipiravir/hydroxychloroquine

Contact Info

Product

Resources

About